Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial

CONCLUSIONS: Lumateperone at 42 mg/day significantly improved depression symptoms and was generally well tolerated in patients with major depressive episodes associated with both bipolar I and bipolar II disorders.PMID:34551584 | DOI:10.1176/appi.ajp.2021.20091339

Source: The American Journal of Psychiatry - September 23, 2021 Category: Psychiatry Authors: Joseph R Calabrese Suresh Durgam Andrew Satlin Kimberly E Vanover Robert E Davis Richard Chen Susan G Kozauer Sharon Mates Gary S Sachs Source Type: research